215 related articles for article (PubMed ID: 11105180)
1. Health and economic benefits of increased beta-blocker use following myocardial infarction.
Phillips KA; Shlipak MG; Coxson P; Heidenreich PA; Hunink MG; Goldman PA; Williams LW; Weinstein MC; Goldman L
JAMA; 2000 Dec; 284(21):2748-54. PubMed ID: 11105180
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China.
Wang M; Moran AE; Liu J; Coxson PG; Heidenreich PA; Gu D; He J; Goldman L; Zhao D
Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):78-85. PubMed ID: 24425706
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.
Choudhry NK; Patrick AR; Antman EM; Avorn J; Shrank WH
Circulation; 2008 Mar; 117(10):1261-8. PubMed ID: 18285564
[TBL] [Abstract][Full Text] [Related]
4. Eliminating out-of-pocket drug costs may improve outcomes after myocardial infarction--but at what cost to Medicare?
Moran A; Goldman L
Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):606-7. PubMed ID: 18695697
[TBL] [Abstract][Full Text] [Related]
5. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction.
Soumerai SB; McLaughlin TJ; Spiegelman D; Hertzmark E; Thibault G; Goldman L
JAMA; 1997 Jan; 277(2):115-21. PubMed ID: 8990335
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
[TBL] [Abstract][Full Text] [Related]
7. Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.
Fidan D; Unal B; Critchley J; Capewell S
QJM; 2007 May; 100(5):277-89. PubMed ID: 17449875
[TBL] [Abstract][Full Text] [Related]
8. Beta-blocker underuse in secondary prevention of myocardial infarction.
Everly MJ; Heaton PC; Cluxton RJ
Ann Pharmacother; 2004 Feb; 38(2):286-93. PubMed ID: 14742768
[TBL] [Abstract][Full Text] [Related]
9. An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors.
Taylor M; Scuffham PA; Chaplin S; Papo NL
Value Health; 2009 Jun; 12(4):459-65. PubMed ID: 19192258
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events.
Sehested TSG; Bjerre J; Ku S; Chang A; Jahansouz A; Owens DK; Hlatky MA; Goldhaber-Fiebert JD
JAMA Cardiol; 2019 Feb; 4(2):128-135. PubMed ID: 30649147
[TBL] [Abstract][Full Text] [Related]
11. Under-utilisation of beta-blockers after acute myocardial infarction. Pharmacoeconomic implications.
Bradford WD; Chen J; Krumholz HM
Pharmacoeconomics; 1999 Mar; 15(3):257-68. PubMed ID: 10537433
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
CDC Diabetes Cost-effectiveness Group
JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure.
Wong FL; Bhatia S; Landier W; Francisco L; Leisenring W; Hudson MM; Armstrong GT; Mertens A; Stovall M; Robison LL; Lyman GH; Lipshultz SE; Armenian SH
Ann Intern Med; 2014 May; 160(10):672-83. PubMed ID: 24842414
[TBL] [Abstract][Full Text] [Related]
14. β-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease.
Andersson C; Shilane D; Go AS; Chang TI; Kazi D; Solomon MD; Boothroyd DB; Hlatky MA
J Am Coll Cardiol; 2014 Jul; 64(3):247-52. PubMed ID: 25034059
[TBL] [Abstract][Full Text] [Related]
15. Adherence to beta-blocker therapy under drug cost-sharing in patients with and without acute myocardial infarction.
Schneeweiss S; Patrick AR; Maclure M; Dormuth CR; Glynn RJ
Am J Manag Care; 2007 Aug; 13(8):445-52. PubMed ID: 17685825
[TBL] [Abstract][Full Text] [Related]
16. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
[TBL] [Abstract][Full Text] [Related]
17. Effects of β-blockers on all-cause mortality in patients with type 2 diabetes and coronary heart disease.
Tsujimoto T; Sugiyama T; Kajio H
Diabetes Obes Metab; 2017 Jun; 19(6):800-808. PubMed ID: 28094466
[TBL] [Abstract][Full Text] [Related]
18. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project.
Krumholz HM; Radford MJ; Wang Y; Chen J; Heiat A; Marciniak TA
JAMA; 1998 Aug; 280(7):623-9. PubMed ID: 9718054
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction.
Ganz DA; Kuntz KM; Jacobson GA; Avorn J
Ann Intern Med; 2000 May; 132(10):780-7. PubMed ID: 10819700
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
